Blueprint Medicines Lands $40,000,000 Series A Financing Round
-
Feed Type
-
Link
http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=da01941f-0ed2-4b42-8e59-ab1172041e41&Preview=1 -
Date
4/11/2011 -
Company Name
Blueprint Medicines -
Mailing Address
Undisclosed Cambridge, MA 02138 -
Company Description
Blueprint Medicines is driving the development of personalized, highly-selective cancer therapies that harness the growing understanding of the molecular blueprint of cancer. -
Website
http://www.blueprintmedicines.com -
Transaction Type
Venture Equity -
Transaction Amount
$40,000,000 -
Transaction Round
Series A -
Proceeds Purposes
Proceeds from the financing will be used to develop new cancer therapies – using the company’s proprietary compound library and Insights-to-Validation™ Platform – that target the driver molecular aberrations of cancer and emerging resistance mechanisms unique to certain cancer patients. -
M&A Terms
-
Venture Investor
Third Rock Ventures -
Venture Investor
Third Rock Ventures -
Venture Investor
Undisclosed
